NCT07118670View on ClinicalTrials.gov

High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

April 30, 2028

Conditions

Proliferative Diabetic Retinopathy (PDR)

Interventions

DRUG

Aflibercept 8mg

Solution in Vial, intravitreal (IVT) injection

All Listed Sponsors

collaborator

Greater Houston Retina Research

OTHER

lead

Edward Wood, MD

OTHER